文献速递妇科

利用自然杀伤细胞治疗卵巢癌

Harnessing natural killer cells for the treatment of ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-04-05

该综述基于Pubmed和clinicaltrials.gov的文献检索,总结了NK细胞治疗卵巢癌的临床前证据和当前试验。仅6项临床试验报告31例卵巢癌患者接受NK细胞过继转移,多数达到疾病稳定且副作用轻微,重复输注者完全缓解更多。所有已报告研究采用静脉输注,正在招募的研究探索腹腔输注同种异体NK细胞。

要点

  • 卵巢癌是免疫原性疾病,NK细胞无需预先致敏即可杀伤肿瘤细胞。
  • 已报告的31例接受NK细胞过继转移的卵巢癌患者多数达到疾病稳定,副作用轻微。
  • 重复输注NK细胞的患者中观察到更多完全缓解,当前在研试验探索腹腔输注。

核心结论

  • NK细胞过继免疫治疗在卵巢癌中显示一定治疗潜力,但需克服挑战才能显著改善疾病结局。

研究设计与样本

  • 综述类研究,检索Pubmed数据库和国际临床试验注册库clinicaltrials.gov。

主要发现

  • 6项临床试验仅报告31例卵巢癌患者接受NK细胞过继转移。
  • 多数患者达到疾病稳定,副作用轻微。
  • 重复输注患者中描述更多完全缓解。
  • 所有已报告研究调查静脉输注NK细胞,正在招募的研究调查腹腔输注同种异体NK细胞。

临床怎么用

  • 卵巢癌患者可考虑NK细胞过继免疫治疗,尤其重复输注可能提高缓解率。
  • 当前证据支持静脉输注途径,腹腔输注尚在研究中。

局限性

  • 已报告的临床数据有限,仅31例患者。
  • 缺乏大规模随机对照试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adoptive cellular immunotherapy could be an interesting new treatment option for ovarian carcinoma (OC), as research has demonstrated that OC is an immunogenic disease. In particular, natural killer (NK) cells have attracted attention due to their ability to kill tumor cells without prior sensitization. The therapeutic value of allogeneic NK cells has been first observed in hematological cancers and is increasingly being explored in solid tumors. METHODS: To substantiate the rationale for NK cell therapy in OC we performed a literature search in the Pubmed database and in the international trial register clinicaltrials.gov with attention for the effect of OC on NK cell function, the effect of current treatment on NK cell biology and the evidence on the therapeutic value of NK cell therapy against OC. RESULTS: In six clinical trials only 31 OC patients have been reported that received NK cell adoptive transfer. The majority of patients reached stable disease after NK cell therapy, with a mild pattern of side effects. In patients who received repeated infusions, more complete responses are described. All reported studies investigated the intravenous infusion of NK cells. Whereas the studies that are currently recruiting, investigate intraperitoneal infusion of allogeneic NK cells. CONCLUSION: In this review the pre-clinical evidence and current trials on NK cell immunotherapy in OC patients are summarized. Furthermore, challenges that have to be overcome for NK cell adoptive therapy to have a significant impact on disease outcome are discussed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hoogstad-van Evert JS, Bekkers R, Ottevanger N, et al. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol. 2020. PMID: 32268953. doi:10.1016/j.ygyno.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。